The registration clinical study conducted in China of GPN00289, a global innovative temperature-sensitive embolic agent product of the Group, for transarterial chemoembolization of primary liver cancer has completed all patients’ enrollment recently. The study is a prospective, multi-center, randomized, parallel-controlled clinical study. It aims to evaluate the safety and effectiveness of GPN00289 for transarterial chemoembolization of primary liver cancer. The completion of all patients’ enrolment in the registration clinical study of GPN00289 is another major R&D progress of the Group in the direction of tumor intervention in the field of nuclear medicine anti-tumor diagnosis and treatment.
- GPN00289 is a temperature sensitive embolic material that granted innovative medical device qualification certification by the National Medical Products Administration of China (NMPA) for the treatment of hypervascular benign and malignant tumors.
- GPN00289 has the characteristics of temperature response and high plasticity. It can undergo liquid-solid phase transition with changes in temperature, and can embolize blood vessels of different sizes and shapes.
- Based on the drug-carrying function of GPN00289, in addition to being used in combination with existing chemotherapy drugs, it is also expected to be used in combination with the Group’s global innovative internal radiotherapy drug, YiGanTai Y-90 microsphere injections.
